Articles

Linear Capital received multiple honors at ChinaVenture, including "China's Best Early-Stage VC Firm" and the "Ten-Year Achievement Award for Venture Capital and Private Equity Firms."

Linear Capital received multiple honors at ChinaVenture, including "China's Best Early-Stage VC Firm" and the "Ten-Year Achievement Award for Venture Capital and Private Equity Firms."

In April 2025, ChinaVenture and its parent company held the 19th China Investment Annual Conference & Annual Summit in Beijing, releasing the 19th ChinaVenture Awards. Linear Capital was named to the "ChinaVenture 2024 China Best Early-Stage VC Firms" and "ChinaVenture 2024 China Best Investment Firms in AI and Big Data" lists, and was also recognized as "ChinaVenture 2024 China Venture Capital and Private Equity Investment..."

Heyuan Medical Closes Funding Round Exceeding RMB 100 Million, Dalton Venture Co-Leads Investment, Multiple Breakthrough Technologies Empower Heart Failure Management | Dalton Venture News

Heyuan Medical Closes Funding Round Exceeding RMB 100 Million, Dalton Venture Co-Leads Investment, Multiple Breakthrough Technologies Empower Heart Failure Management | Dalton Venture News

Recently, **Shanghai-based United InnoMed® announced the completion of a new funding round exceeding 100 million RMB**. The round was **jointly led by Dalton Venture and Dragonstone Capital**, with follow-on investments from Yinglian Health Fund and Tianrui Fengnian Capital. Existing investor Lilly Asia Ventures continued to increase its stake. **The proceeds will be primarily used for the R&D and registration clinical trials of multiple core pipeline products.**